Ismail Bobat, MD
Pulmonary Disease · Urbana, ILNPI 1750310553
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,134 of the $58,350 with a category attached, or 84.2%. AstraZeneca accounts for 83.9% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $28,372, 8.8 times the $3,212 reported in 2019. Among pulmonary disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 177 payments — averaging $329.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$49K
- Verona Pharma, Inc.$6K
- Johnson & Johnson$977
- Sanofi$487
- Regeneron Healthcare Solutions, Inc.$386
- Boehringer Ingelheim$336
- plus $1K from 12 others
What the payments were for
- Speaking & faculty fees$49,13484%
- Travel & lodging$4,5058%
- Food & beverage$4,0757%
- Education$6371%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 71 | $48,931 |
| Verona Pharma, Inc. | 6 | $6,232 |
| Johnson & Johnson(2 entities) | 3 | $977 |
| Sanofi | 24 | $487 |
| Regeneron Healthcare Solutions, Inc. | 13 | $386 |
| Boehringer Ingelheim | 15 | $336 |
| GSK | 17 | $285 |
| Inspire Medical Systems, Inc. | 2 | $230 |
| Grifols USA, LLC | 6 | $128 |
| Merck | 1 | $72 |
| Insmed, Inc. | 3 | $64 |
| Mylan Specialty L.p. | 3 | $54 |
| Electromed, Inc. | 6 | $51 |
| Axsome Therapeutics, Inc. | 2 | $30 |
| Pulmonx Corporation | 2 | $28 |
| Lilly USA, LLC | 1 | $28 |
| Resmed Corp | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,350 in reported general payments places this provider in the 95th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 39 | $467,598 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 467 | $330,940 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 445 | $305,328 |
| Spiriva RespimatTiotropium Bromide | 72 | $41,316 |
| Breo ElliptaFluticasone/Vilanterol | 101 | $39,260 |
| Incruse ElliptaUmeclidinium Bromide | 47 | $20,883 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 90 | $16,438 |
| SymbicortBudesonide/Formoterol Fumarate | 68 | $15,487 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 585 | $15,401 |
| Montelukast Sodium | 1,664 | $12,453 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $11,378 |
| Varenicline Tartrate | 37 | $9,306 |
| DuleraMometasone/Formoterol | 25 | $8,659 |
| Ventolin HfaAlbuterol Sulfate | 87 | $5,760 |
| BreynaBudesonide/Formoterol Fumarate | 33 | $5,326 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $336 | $520,292131 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $285 | $391,083615 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $48,931 | $320,815513 claims |
| MerckDulera | $72 | $8,65925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Urbana
- Douglas HogarthChicago$2.9M
- Steven WhiteChicago$970K
- Momen WahidiChicago$779K
- Septimiu MurguChicago$633K
- Ayodeji AdegunsoyeChicago$561K
- Kristopher McDonoughJoliet$461K
- Ravi KalhanChicago$375K
- Brian GaribaldiChicago$356K
- Danish ThameemChampaign$353K
- Bradford BemissMaywood$259K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.